Results 41 to 50 of about 940 (189)
BRD9 inhibition as potential treatment option for testicular germ cell tumors
Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen +5 more
wiley +1 more source
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam +7 more
wiley +1 more source
ABSTRACT Background Familial clustering of testicular germ cell tumour (TGCT) is well‐established, whereas the risk of non‐testicular cancer among relatives remains inconsistent across studies. Objective To evaluate the overall and site‐specific cancer risk among first‐degree relatives and grandparents of TGCT patients compared to cancer‐free controls.
Csilla Krausz +13 more
wiley +1 more source
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick +7 more
wiley +1 more source
Cistoadenocarcinoma mucinoso de páncreas
El cistoadenocarcinoma mucinoso de páncreas representa entre un 6- 36% del total de las neoplasias quísticas mucinosas de páncreas. Son tumores únicos localizados en cuerpo o cola de páncreas con un tamaño que varia entre 6 y 36 cm.
Néstor Ricardo Davies +4 more
doaj +1 more source
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu +4 more
wiley +1 more source
Targeting KRAS for cancer therapy
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
Tratamiento quirúrgico del cáncer de recto, revisión bibliográfica
En los últimos 25 años, la historia del cáncer de recto ha cambiado al pasar el tratamiento de quirúrgico a un modelo multidisciplinario. La estadificación adecuada tiene un rol crítico en el proceso de toma de decisiones en pacientes con cáncer de recto.
Audel Pedroza
doaj
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff +3 more
wiley +1 more source
In cystic fibrosis disorder, CFTR dysfunction drives multilayered intestinal niche disruption, including dysbiosis, inflammation, hypoxia, metabolic stress and genotoxic injury, promoting cell‐state plasticity and a pre‐neoplastic ecosystem. CFTR modulators and environmental factors may partially reshape these processes, highlighting opportunities for ...
Bala Umashankar +5 more
wiley +1 more source

